ArticleClinical chemistry2013
Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies.
Article in Clinical chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Guideline
- LC‑MS/MS for Thyroglobulin: A Complementary Approach to Immunoassay Limitations for Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Clinical Utility of Liquid Chromatography-Tandem Mass Spectrometry for Thyroglobulin Measurement in Comparison with Immunoradiometric Assay and Chemiluminescence Microparticle Immunoassay.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Revisiting Thyroglobulin Measurement: Current Methods and Future Perspectives Using Dried Blood Spot Sampling for Enhanced Clinical Practice.Metabolites · 2025Review
- National recommendations of the Croatian society of medical biochemistry and laboratory medicine: Thyroid function tests from the laboratory point of view.Biochemia medica · 2025Review
- Biomarkers, Proteoforms, and Mass Spectrometry-Based Assays for Diabetes Clinical Research.The Journal of clinical endocrinology and metabolism · 2025Review
- The Relationship Between Serum Levels of Thyroglobulin Antibody and the Risk of Recurrence in Patients With Differentiated Thyroid Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA.The Journal of clinical endocrinology and metabolism · 2024Article
- Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer.Journal of clinical medicine · 2024Review
- Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers.Clinical proteomics · 2024Review
- Plasma/Serum Proteomics based on Mass Spectrometry.Protein and peptide letters · 2024Review
- Cheaper, faster, simpler trypsin digestion for high-throughput targeted protein quantification.Journal of mass spectrometry and advances in the clinical lab · 2023Article
- Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER.Journal of proteome research · 2023Article
- Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests.Journal of mass spectrometry and advances in the clinical lab · 2023Review
- Automated proteomic sample preparation: The key component for high throughput and quantitative mass spectrometry analysis.Mass spectrometry reviews · 2023Review
- Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.Cancer discovery · 2023Article
- Clinical irrelevance of lower titer thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma.European thyroid journal · 2022Article
- A distributable LC-MS/MS method for the measurement of serum thyroglobulin.Journal of mass spectrometry and advances in the clinical lab · 2022Article
- The triple quadrupole: Innovation, serendipity and persistence.Journal of mass spectrometry and advances in the clinical lab · 2022Article
- Review of the Use of Liquid Chromatography-Tandem Mass Spectrometry in Clinical Laboratories: Part I-Development.Annals of laboratory medicine · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMeasurement of serum thyroglobulin (Tg) is used to monitor patients after treatment for differentiated thyroid carcinoma (TC). Difficulty in using Tg as a biomarker of the recurrence of TC in many patients stems from the presence of endogenous anti-Tg autoantibodies (Tg-AAbs), which can interfere with immunoassays (IAs) and cause false-negative results.
methodsWe enriched Tg from serum samples using rabbit polyclonal anti-Tg antiserum and protein precipitation. Unrelated proteins were partially depleted in the process. Enriched proteins were then denatured, reduced, and digested with trypsin after the addition of a winged internal standard peptide. A Tg-specific tryptic peptide was purified by immunoaffinity extraction and analyzed by 2-dimensional LC-MS/MS. Instrument cycle time was 6.5 min per sample.
resultsThe lower limit of quantification was 0.5 ng/mL (0.76 fmol/mL dimer). Total imprecision of triplicate measurements in serum samples over 5 days was <10%. Comparison with a commercial IA using serum samples free of Tg-AAb (n = 73) showed Deming regression, IA = 1.00 * LC-MS/MS - 2.35, r = 0.982, standard error of the estimate (S(y|x)) = 9.52. In a set of Tg-AAb-positive samples that tested negative for Tg using IA (n = 71), concentrations determined by LC-MS/MS were ≥0.5 ng/mL in 23% of samples (median 1.2, range 0.7-11 ng/mL).
conclusionsThe introduced method has acceptable performance characteristics for use in clinical diagnostic applications. The most substantial disagreement between methods was observed in Tg-AAb-positive samples with concentrations <2 ng/mL (determined with LC-MS/MS). The affinity-assisted enrichment strategy used for Tg in this method should be applicable to other biomarkers that have endogenous autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.